Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

NCT06477406 · ctgov active_not_recruiting phase phase-2
Enrollment
30
Start
2024-02-27
Completion
2026-12-01
Last updated
2026-09-30
Has results
False
Countries
United States

Conditions

Endometriosis

Tagged with

endometriosis

Interventions

Eligibility criteria
Inclusion Criteria: 1. Subject has provided informed consent 2. Sex assigned female at birth 3. Subject is 21 or older 4. Subject is fluent in English 5. Subject endorses at least moderate levels of pain at the baseline visit 6. Subject endorses having endometriosis Exclusion Criteria: 1. Non-fluent English speakers 2. Endorsement of current substance use disorder, psychotic disorder, or an eating disorder 3. Currently uses cannabis or cannabinoid products regularly 4. Patients will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding 5. Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder) 6. Neuropathic pain or cancer-related pain 7. Disclosure of a genetic polymorphism affecting CYP2C9 function
License: public-domain-us · commercial use OK · attribution required
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine

No linked papers in the corpus yet.